Warning Letter Analysis7 min read

Amazon and Walmart FDA warning letters: herpes remedies their warehouses shipped

FDA bought herpes remedies on Amazon and Walmart.com, then warned both platforms and eight sellers. Amazon's 10th letter since 2022 shows what the fulfillment theory means for sellers.

Amazon and Walmart FDA warning letters: herpes remedies their warehouses shipped

On October 6, FDA posted ten warning letters dated October 1. All ten came from the drug center (CDER), and all ten concern products sold to treat or relieve sexually transmitted infections, mostly genital herpes. Eight went to the companies that make or sell the products. Two went to Amazon and Walmart, which made none of them.

The Amazon letter (MARCS-CMS 736006) is the tenth FDA warning letter addressed to Amazon.com, Inc. since August 2022, by a search of FDA's warning letter database. The Walmart letter (MARCS-CMS 736557) is Walmart's fifth by the same search. In June we covered Amazon's ninth letter. This one is a bigger test of the same theory, because it arrived as part of a coordinated sweep.

What FDA bought, and who it blamed

FDA purchased the products in July 2026. From Amazon it bought nine: FemiClear, HClear for him, HerpCare Ointment, HerpCare Spray, Herstat GST, Genital Herpes Ointment, RoyceDerm Herpes Relief Cream, Terragen HG Formula and Genital Herpes Intimate Wash. From Walmart.com it bought three: HClear for him, Herstat GST and Terragen HG Formula.

The legal theory is the same in both letters. The products are drugs because their labeling claims to treat a disease, new drugs because they are not generally recognized as safe and effective, and unapproved because no application exists. Introducing them into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act.

The platform-specific part is one sentence and a footnote. Each letter says the platform "distributed each of the products directly to individual U.S. consumers on behalf of third parties" and that every product was "fulfilled" by it. FDA then quotes the platforms' own seller pages back to them. For Amazon: "we'll pick, pack, and ship orders." For Walmart Fulfillment Services: "we'll pick, pack and ship the item to the customer on the seller's behalf."

FDA's framing of the risk is blunt. The letters say FDA "has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI," and warn that people relying on these products "may forgo timely, appropriate medical care," with risks including infertility and sepsis, and may pass infections to partners.

A correction to our June post

When we wrote about the ninth Amazon letter in June, we said its Fulfillment by Amazon clause was new. That was wrong. We have since read all ten letters FDA has sent Amazon. Every one, starting with the August 2022 letter over mole and skin tag removers, says the products were introduced into interstate commerce "by Amazon via your Fulfillment by Amazon service." Four of Walmart's five letters make the same argument about Walmart Fulfillment Services. The exception is Walmart's December 2025 letter, which concerned its handling of the ByHeart infant formula recall.

So the fulfillment theory is not a 2026 development. FDA has used it in every letter to Amazon for four years. Our reading is that this matters more than a new clause would: for FDA, holding a marketplace responsible for what its warehouses ship is settled practice, and nothing in the October letters treats it as an open question.

The 2023 molluscum letters were the template

The October sweep follows a structure FDA used in August 2023. On August 22 of that year, FDA posted six warning letters, all dated August 18, over products sold to treat molluscum contagiosum, a viral skin infection: one each to Amazon and Walmart, and one each to Molluscumaway, MolluscumRx, Nature's Innovation and Thrasio (doing business as ZymaDerm).

October 2026 is the same design at a larger scale: two platform letters and eight seller letters, all on one disease category, all posted the same day. The two platforms also tend to be warned together. Four of Walmart's five letters were issued on the same day as a letter to Amazon (October 2022, August 2023, July 2024 and October 2026).

Our interpretation, which FDA has not stated: the platform letter does the fast work, because one letter can clear listings from many sellers, and the seller letters build the record if FDA escalates against a brand.

"Homeopathic" on the label did not help

Six of the nine products on the Amazon list are labeled homeopathic. FDA spent a footnote explaining why that changed nothing.

FDA's December 2022 guidance on homeopathic drugs sets enforcement priorities for products labeled homeopathic that contain only active ingredients listed in the Homeopathic Pharmacopeia of the United States (HPUS). FemiClear, HClear for him, HerpCare Ointment, HerpCare Spray and Genital Herpes Ointment all contain lemongrass, which is not listed in the HPUS. That puts them outside the guidance entirely. FDA added that even if they were inside it, they would land in the category it "intends to prioritize for enforcement": homeopathic products marketed without required approval that pose higher risks.

The two seller letters aimed at classic homeopathic remedies make the same point from the other side. DesBio's "CHLA:10M" contains Chlamydia trachomatis 10M, which is also not in the HPUS. The Platinum Healthcare's "Sycosis" and "Syphillinum" use homeopathic vocabulary and were sold as oral antigens against the "Gonorrhea miasm" and "Syphilis miasm." Terragen HG Formula is labeled homeopathic with homeopathic strengths, and FDA's answer was that homeopathic drugs face the same approval, adulteration and misbranding requirements as any other drug.

Herstat tried the OTC monograph route

Herstat GST is the only product in the sweep that FDA tested against an OTC monograph. Monograph M017 covers external analgesics, and FDA says its permitted indications are "pain, itching, and minor skin irritation generally" plus prevention of premature ejaculation. Herstat's labeling says "Genital Sore Treatment" and "relieves pain and itching associated with genital sores." FDA's position is that treating genital sores "goes beyond the permissible indications under M017," so the product has no basis under section 505G (added by the CARES Act in 2020) and needs an approved application.

This is the practical line for anyone selling a topical analgesic. Pain and itching relief is monograph territory. Tie that relief to a named disease, or to sores caused by one, and the monograph no longer covers you.

The claims FDA quoted

The letters show which phrases did the work:

  • FemiClear and HClear for him: ">90% OF USERS REPORTED LESS SEVERE OUTBREAKS" and "[B]est used at first sign of outbreak."
  • RoyceDerm Herpes Relief Cream: "FIGHTS OUTBREAKS" and "REDUCES RECURRENCE," plus before-and-after images of lesions on its website.
  • Genital Herpes Intimate Wash: "Antiviral Action . . . reduce viral activity."
  • Graceful Touch's "Herpes B Gone": "Lower the dangers of herpes virus."

FDA did not stop at the label. The OrganiCare letter quotes a September 10, 2024 Facebook post claiming HClear "kills 99.9% of herpes simplex viruses." The Aidance Scientific letter notes that its website's "Shop by Condition" menu sends users who click "Herpes" to its Amazon storefront, then quotes the Amazon listing: "Genital sores treatment, outbreak support." Social posts two years old and marketplace listing copy were both treated as evidence of intended use under 21 CFR 201.128.

What to do if you sell on a marketplace

If you sell topical OTC, homeopathic or "natural" skin products on Amazon or Walmart:

  1. Search your titles, bullets, images, A+ content and back-end search terms for disease names: herpes, outbreak, cold sore, STI, chlamydia, molluscum, phimosis. In this batch FDA quoted a brand's Amazon listing as evidence against it. Remove any condition name you can't support with an approval or a monograph.
  2. If you rely on an OTC monograph, check every claim against that monograph's exact indications. "Itching" fits M017. "Genital sore treatment" does not.
  3. Don't count on a homeopathic label. If any active ingredient is missing from the HPUS (lemongrass was enough here), the 2022 guidance does not apply to you.
  4. Audit your old social posts. FDA quoted one from 2024.

If you sell no drug-like products, or make no disease claims: no action is needed on these letters.

What we would watch next: whether FDA names the remaining Amazon seller, whose "Genital Herpes Ointment" has no matching seller letter in this batch, and whether any platform ever contests the fulfillment theory in writing.

Sources

  • FDA warning letters dated October 1, 2026, posted October 6: Amazon.com, Inc. (736006), Walmart, Inc. (736557), OrganiCare (734925), Terramed (735070), Bioactive Services USA / Herstat (734784), RoyceDerm (734781), Aidance Scientific (735346), Graceful Touch (735272), DesBio/Deseret Biologicals (735464), The Platinum Healthcare (735147)
  • Earlier FDA warning letters to Amazon.com, Inc. (629452, 631751, 649056, 665460, 662503, 679523, 695821, 689355, 728814) and Walmart, Inc. (631755, 648620, 683095, 720400); August 18, 2023 molluscum letters to Molluscumaway, MolluscumRx, Nature's Innovation and Thrasio (ZymaDerm); FDA Warning Letters database
  • FDA, Homeopathic Drug Products: Guidance for FDA Staff and Industry (December 2022); OTC Monograph M017, External Analgesic Drug Products for OTC Human Use
  • FD&C Act sections 201(g)(1), 201(p), 301(d), 505(a), 505G; 21 CFR 201.128

Policy Canary tracks every FDA action, warning letters, recalls, guidance, and rules, against the specific products you make, by name and by ingredient. See what we would flag for your products.

Get this in your inbox every Friday.

Free FDA intelligence digest. No account required.

Share this article

More in Warning Letter Analysis

What if this analysis was about YOUR products?

Policy Canary monitors the FDA for your specific products — by name, by ingredient, by facility. Start your free trial.

Start Free Trial